Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-58067 in Advanced Solid Tumors
NCT06589596Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jan 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of BGB-58067 in solid tumor (advanced stage) (6 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events at 13 months, Number of Participants with Adverse Events that meet Dose-Limiting Toxicity criteria at 1 month and 4 more. Started Jan 2025; status: recruiting.
02
Drugs
BGB-58067
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06589596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589596.